Research Article

Immunology and Cell Biology (1995) 73, 66–72; doi:10.1038/icb.1995.11

Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells

Fang F Yuan1, Jennifer A Bryant1 and Anne Fletcher1

1NSW Red Cross Blood Transfusion Service, Sydney, New South Wales, Australia

Correspondence: Dr Anne Fletcher, NSW Red Cross Blood Transfusion Service, 153 Clarence Street, Sydney, NSW 2000, Australia.

Received 29 April 1994; Accepted 11 July 1994.

Top

Abstract

The increased susceptibility to homologous complement in paroxysmal nocturnal haemoglobinuria (PNH) is known to be associated with the deficiency of the membrane complement inhibitors CD59 and CD55. Proteases have been used in this study to modify normal human RBC to complement sensitive PNH-like cells. To investigate the protective role of CD59 and CD55, the relationship between the content of CD59 and CD55 and the complement susceptibility of the PNH-like cells has been determined. The differential resistance of the enzyme-treated RBC to complement-mediated injury was measured by acidified serum lysis. Pronase-treated erythrocytes lacked both CD59 and CD55 and were very susceptible to complement-mediated lysis. Papain treatment of RBC reduced the CD55 content but did not affect CD59 and induced slight susceptibility to complement-mediated lysis. Trypsin treatment of RBC destroyed 80% of CD59, had little effect on CD55 (unless incubation was extended) and slightly increased susceptibility to lysis. Thus, partial CD55 and CD59 activity was sufficient to protect cells from complement-mediated lysis. In the reactive lysis assay, anti-CD55 and anti-CD59 induced haemolysis, anti-CD59 having the more pronounced effect. Lysis was enhanced when RBC were treated by both antibodies simultaneously.

Keywords:

CD55, CD59, complement, paroxysmal nocturnal haemoglobinuria, protease.

Top

References

  1. Fearon, DT. 1979. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc. Natl Acad. Sci. USA 76: 5867–5871. | Article | PubMed | ChemPort |
  2. Seya, T, Turner, JR and Atkinson, JP. 1986. Purification and characterization of a membrane protein (gp45–70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163: 837–855. | Article | PubMed | ISI | ChemPort |
  3. Nicholson-Weller, A, Burge, J, Fearon, DT, Weller, PF and Austen, KF. 1982. Isolation of a human erythrocyte membrane glycoprotein with decay accelerating activity for C3 convertases of the complement system. J. Immunol 129: 184–189. | PubMed | ChemPort |
  4. Schönermark, S, Rauterberg, EW, Shin, ML, Löke, S, Roelcke, D and Hänsch, GM. 1986. Homologous species restriction in lysis of human erythrocytes: A membrane derived protein with C8-binding capacity functions as an inhibitor. J. Immunol 136: 1772–1776.
  5. Zalman, LS, Wood, LM and Müller-Eberhard, HJ. 1986. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc. Natl Acad. Sci. USA 83: 6975–6979. | Article | PubMed | ChemPort |
  6. Watts, MJ, Dankert, JR and Morgan, BP. 1990. Isolation and characterization of a membrane-attack-complex- inhibiting protein present in human serum and other biological fluids. Biochem. J. 265: 471–477.
  7. Walsh, LA, Tone, M, Thiru, S and Waldmann, H. 1992. The CD59 antigen-a multifunctional molecule. Tissue Antigens 40: 213–220. | PubMed | ISI | ChemPort |
  8. Venneker, GT and Asghar, SS. 1992. CD59: A molecule involved in antigen presentation as well as downregulation of membrane attack complex. Exp. Clin. Immunogenet. 9: 33–47.
  9. Pangburn, MK, Schreiber, RD and Müller-Eberhard, HJ. 1983. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc. Natl Acad. Sci. USA 80: 5430–5434. | Article | PubMed | ChemPort |
  10. Medof, ME, Kinoshita, T and Nussenzweig, V. 1984. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med 160: 1558–1578. | Article | PubMed | ISI | ChemPort |
  11. Meri, S, Morgan, BP, Davies, A et al. 1990. Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71: 1–9.
  12. Rollins, SA and Sims, PJ. 1990. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J. Immunol. 144: 3478–3483. | PubMed | ChemPort |
  13. Lehto, T and Meri, S. 1993. Interactions of soluble CD59 with the terminal complement complexes: CD59 and C9 compete for a nascent epitope on C8. J. Immunol 151: 4941–4949. | PubMed | ChemPort |
  14. Schönermark, S, Filsinger, S, Berger, B and Hänsch, GM. 1988. The C8-binding protein of human erythrocytes: Interaction with the components of the complement-attack phase. Immunology 66: 585–590.
  15. Rosse, WF. 1990. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 75: 1595–1601.
  16. Yomtovian, R, Prince, GM and Medof, ME. 1993. The molecular basis for paroxysmal nocturnal hemoglobinuria. Transfusion 33: 852–873.
  17. Miyata, T, Takeda, J, Iida, Y et al. 1993. The cloning of PIG-A. a component in the early step of GPI-anchor biosynthesis. Science 259: 1318–1320. | Article | PubMed | ISI | ChemPort |
  18. Takeda, J, Miyata, T, Kawagoe, K et al. 1993. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73: 703–711. | Article | PubMed | ISI | ChemPort |
  19. Rosse, WF, Hoffman, S, Campbell, M, Borowitz, M, Moore, JO and Parker, CJ. 1991. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis. Br. J. Haematol. 79: 99–107.
  20. Fletcher, A, Bryant, JA, Gardner, B et al. 1992. New monoclonal antibodies in CD59: Use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes. Immunology 15: 507–512.
  21. Spring, FA, Judson, PA, Daniels, GL, Parsons, SF, Mallinson, G and Anstee, DJ. 1987. A human cell-surface glycoprotein that carries Cromer-related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets. Immunology 62: 307–313.
  22. Anstee, DJ, Ridgwell, K, Tanner, MJA, Daniels, GL and Parsons, SF. 1984. Individuals lacking the Gerbich blood-group antigen have alterations in the human erythrocyte membrane sialoglycoproteins beta and gamma Biochem. J. 221: 97–104.
  23. Advani, H, Zamor, J, Judd, WJ, Johnson, CL and Marsh, WL. 1982. Inactivation of Kell blood group antigens by 2-aminoethylisothiouronium bromide. Br. J. Haemalol. 51: 107–115.
  24. Okada, N, Harada, R, Fujita, T and Okada, H. 1989. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J. Immunol. 143: 2262–2266. | PubMed | ChemPort |
  25. Seya, T, Inoue, H, Okada, M et al. 1990. Proteolytic elimination of decay-accelerating factor (DAF): Lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes. Mol. Immunol. 27: 69–78.
  26. Ezzell, JL, Wilcox, LA, Bernshaw, NJ and Parker, CJ. 1991. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes; Effects of 2-aminoethyIisothiouronium bromide on membrane proteins that regulate complement. Blood 71: 2764–2773.
  27. Yachnin, S, Laforet, MT and Gardner, FH. 1961. PH dependent hemolytic systems. I. Their relationship to paroxysmal nocturnal haemoglobinuria. Blood 17: 83–93. | PubMed | ISI | ChemPort |
  28. Holguin, MH, Wilcox, LA, Bemshaw, NJ, Rosse, WF and Parker, CJ. 1989. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 84: 1387–1394.
  29. Merry, AH, Rawlinson, VI, Uchikawa, M, Daha, MR and Sim, RB. 1989. Studies on the sensitivity to complement- mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Br. J. Haematol. 73: 248–253.
  30. Telen, MJ and Green, AM. 1989. The Inab phenotype: Characterization of the membrane protein and complement regulatory defect. Blood 14: 437–441.
  31. Miyagawa, S, Shirakura, R, Matsumiya, G et al. 1993. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes. Scand. J. Immunol. 38: 37–44.
  32. Yamashina, M, Ueda, E, Kinoshita, T et al. 1990. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 323: 1184–1189. | PubMed | ISI | ChemPort |
  33. Wilcox, LA, Ezzell, JL, Bernshaw, NJ and Parker, CJ. 1991. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. Blood 78: 820–829. | PubMed | ISI | ChemPort |

Extra navigation

.

naturejobs

More science jobs
Post a job for free
ADVERTISEMENT